|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Total Current Assets | ||||||||||||||
| Cash held in trust account | ||||||||||||||
| Total Assets | ||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||
| Current liabilities | ||||||||||||||
| Accrued expenses | ||||||||||||||
| Accounts payable | ||||||||||||||
| Other liabilities | ||||||||||||||
| Franchise tax payable | ||||||||||||||
| Income tax payable | ||||||||||||||
| Extension loans | ||||||||||||||
| Working capital loan | ||||||||||||||
| Excise tax liability | ||||||||||||||
| Total Current Liabilities | ||||||||||||||
| Deferred underwriter commission | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Common Stock subject to possible redemption; 101,216 shares (at $5.05 per share) as of March 31, 2025 and 1,717,663 shares (at $11.55 per share) as of December 31, 2024 | ||||||||||||||
| Stockholders’ Deficit | ||||||||||||||
| Common Stock, $0.000001 par value, 100,000,000 shares authorized; 2,990,897 issued and outstanding (excluding 101,216 shares and 1,717,663 shares subject to possible redemption as of March 31, 2025 and December 31, 2024 respectively) | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||
| Total Liabilities and Stockholders’ Deficit | ||||||||||||||
Loading...
